Mubadala Capital, Cain International to deploy bns in luxury real estate: Mubadala Capital partnered with London-based alternative asset manager Cain International to invest bns of USD in luxury property, sources familiar with the matter told Bloomberg. The funds will be used to expand some of the firms’ existing portfolios and pursue new investments in the sector.

Background: Cain CEO Jonathan Goldstein mentioned the Mubadala Capital partnership in an interview with Bloomberg (watch, runtime: 1:31:10) earlier last month, without disclosing details. He mentioned plans to diversify into other regions, and name-checked the Middle East’s Dubai, Abu Dhabi, Saudi Arabia, and Bahrain, as offering “pockets of huge growth.”

The tie-up builds on previous collaboration between the two investors in ultra-luxury hospitality brand Aman Group. Mubadala joined Alpha Wave Ventures in a USD 360 mn funding round for Aman in 2023, alongside Cain and Saudi Arabia’s Public Investment Fund (PIF), which had injected USD 900 mn in 2022 to accelerate its global project pipeline.

About Cain International: The privately held alternative asset manager — a partnership between CEO Jonathan Goldstein (LinkedIn) and US-based Eldridge Industries — manages USD 13.6 bn in assets as of March 2025, with investments spanning real estate equity, credit, and private equity, according to its website.

OTHER MUBADALA NEWS-

Mubadala Capital’s venture arm, Mubadala Capital Ventures, took part in a USD 30 mn funding round for US-based biotech firm Tahoe Therapeutics, according to a press release. The round was led by Amplify Partners, with Databricks Ventures, Wing Venture Capital, and General Catalyst also participating.

Where will the money go? Tahoe will use the proceeds to grow its therapeutic programs and select a single strategic partner from the pharma or AI sectors to access its next-generation cell database.

More on Tahoe: Founded in 2022 by Hani Goodarzi (LinkedIn), Kevan Shokat, and Johnny Yu (LinkedIn), the company is developing AI-powered virtual models of human cells to improve drug discovery. Its platform aims to compile 1 bn single-cell data points for more precise treatments, including cancer drugs.

REMEMBER- Mubadala has been growing its healthcare footprint: Earlier in January, it led a USD 200 mn funding round for the newly launched biotech company Tenvie Therapeutics,

While its biotech arm Kelix bio acquired Julphar’s DiabTec, the GCC’s only EU and US FDA-compliant insulin API plant. It earlier bought Global Medical Supply Chain, Al Ittihad Drug Store, and multiple biopharma assets from Yas Holdings.

Tags: